# Anna F. Farago

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anna-f-farago/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,793 |
| Field | Lung Cancer Research Studies |
| h-index | 53 |
| i10-index | 128 |
| Last Known Institution | Amgen (United States) |
| OpenAlex ID | https://openalex.org/A5066069221 |
| ORCID iD | https://orcid.org/0000-0001-6193-039X |
| Works | 360 |

## Researcher papers

- [Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children](https://scholariq.org/papers/efficacy-of-larotrectinib-in-i-trk-i-fusion-positive-cancers-in-adults-and/)
- [Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-patients-with-advanced-or-metastatic-ntrk-fusion-positive-solid/)
- [<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis](https://scholariq.org/papers/i-egfr-i-mutations-and-i-alk-i-rearrangements-are-associated-with-low-response/)
- [Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials](https://scholariq.org/papers/larotrectinib-in-patients-with-trk-fusion-positive-solid-tumours-a-pooled/)
- [Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)](https://scholariq.org/papers/safety-and-antitumor-activity-of-the-multitargeted-pan-trk-ros1-and-alk/)
- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/patterns-of-metastatic-spread-and-mechanisms-of-resistance-to-crizotinib-in-i/)
- [Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer](https://scholariq.org/papers/combination-olaparib-and-temozolomide-in-relapsed-small-cell-lung-cancer/)
- [Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion](https://scholariq.org/papers/clinicopathologic-features-of-non-small-cell-lung-cancer-harboring-an-i-ntrk-i/)

## Researcher topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Amgen (United States)](https://scholariq.org/institutions/amgen-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.